Tianeptine Side Effects: What Studies Report

What the published literature actually covers

Tianeptine is a dibenzothiazepine compound that has been marketed as an antidepressant in some countries and is not approved by the US Food and Drug Administration for any medical use. Because of that split status, the published record on its adverse effects is not one literature but three: preclinical pharmacology and toxicology in rodents, surveillance and case data describing human exposures outside medical supervision, and the broader antidepressant tolerability literature in which tianeptine appears alongside other agents. These three bodies of work were designed to answer different questions, and they do not translate neatly into one another. This page summarises what each reported. It does not offer instructions, protocols or comparisons intended to guide use. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medication or health-related decision.

Why the adverse-effect discussion is framed in opioid terms

Much of the modern safety discussion follows from pharmacology rather than from clinical trials. A 2022 study in Psychopharmacology characterised opioid-like adverse effects of tianeptine in male rats and mice, and the researchers framed the compound's effect profile in terms normally applied to mu-opioid receptor agonists (PMID 35211768). Separate mechanistic work on mu-receptor activation has examined how structurally unusual ligands engage the receptor through distinctive mechanisms, which is the kind of pharmacology that makes an antidepressant-classified molecule behave in ways clinicians associate with opioids (PMID 39067665).

Tianeptine's chemistry has also been of interest outside psychiatry. A 2022 medicinal-chemistry paper developed dibenzothiazepine derivatives as multifunctional compounds for neuropathic pain, illustrating that this scaffold has been explored for analgesic targets rather than mood effects alone (PMID 35455404). A 2019 study in ACS Chemical Neuroscience reported that antidepressant compounds can modulate proton-gated ion channels, one example of off-target activity that the antidepressant class has been screened for (PMID 30475579). None of these papers reported human adverse-event rates; they describe receptor-level and channel-level activity that forms the background to the clinical reports below.

Opioid-Like Adverse Effects in Animal Studies: What Studies Report

The most direct preclinical safety evidence in the verified literature is the 2022 rodent work. The study administered tianeptine to male rats and mice and reported opioid-like adverse effects, characterising the compound's profile against the effects expected of mu-opioid agonists (PMID 35211768). Researchers reported this profile in two species and in male animals only, which is a stated limitation of scope rather than a finding about sex differences.

Several points follow from how that work was designed:

• The findings were obtained in rodents, and species differences in opioid pharmacology and metabolism are well recognised, so effect magnitudes do not transfer directly to humans.
• The 2022 study described adverse effects in an experimental setting with controlled exposure, not products of unknown content (PMID 35211768).
• Animal work of this type is designed to identify a hazard signal; it does not estimate how often an effect occurs in people.

Human Exposure Reports and Poison Centre Data: What Studies Report

The largest human dataset in this literature is surveillance rather than trial data. A 2018 MMWR report described the characteristics of tianeptine exposures reported to the US National Poison Data System between 2000 and 2017, and the authors reported that exposure calls increased over that period, with cases frequently involving co-exposure to other substances (PMID 30070980). The report described neurological, cardiovascular and gastrointestinal clinical effects among those documented in the calls it reviewed (PMID 30070980).

Poison centre data have structural limitations that the authors of such reports routinely acknowledge. Calls are voluntary and passive, exposure amounts are usually self-reported or unknown, product contents are rarely analytically confirmed, and co-ingestion makes attribution to a single substance difficult. A rise in call volume can reflect increased product availability, increased clinician awareness, or both, and cannot be read as an incidence rate.

A 2025 paper in the Journal of Psychoactive Drugs examined tianeptine products and asked directly whether they represented a public health threat or a niche pattern of substance use, placing the surveillance signal in a population and regulatory context (PMID 41084181). That framing matters because the same body of case data can support either interpretation depending on how denominators and product availability are handled.

Withdrawal and Dependence: What Studies Report

Withdrawal is the adverse outcome most consistently described in the clinical literature. A 2024 case report in Cureus described a tianeptine withdrawal presentation that was obscured in the initial clinical picture, and the authors discussed the presentation and its treatment (PMID 39022455). The report's central observation was diagnostic rather than pharmacological: the syndrome was not immediately recognised as tianeptine-related, which the authors reported as a reason clinicians may underestimate its frequency (PMID 39022455).

That clinical picture is consistent with the preclinical framing, where researchers reported opioid-like adverse effects of tianeptine in rodents (PMID 35211768). Consistency across evidence types is not the same as quantification, however. A single case report cannot establish how commonly withdrawal occurs, what exposure patterns precede it, or which management approaches perform best in comparison.

Tolerability in the antidepressant trial literature

Where tianeptine has been used as a prescription antidepressant, its adverse-effect profile has been assessed through the same machinery applied to other agents: randomised trials, dropout-due-to-adverse-events measures and network meta-analyses. A 2023 network meta-analysis in Molecular Psychiatry compared antidepressants for adults with major depressive disorder in the maintenance phase and reported both efficacy and tolerability outcomes across the compared drugs (PMID 36253442). Reviews of this design summarise average tolerability across trial populations that were screened, monitored and treated at prescribed exposures.

This is the key interpretive divide in the tianeptine safety literature. Trial-derived tolerability estimates describe supervised therapeutic use; poison centre reports and withdrawal case reports describe exposures that were neither supervised nor dose-verified (PMID 30070980). Researchers reported these outcomes in different populations, and the published record does not contain a head-to-head comparison that reconciles them.

Special populations and stated evidence gaps

The verified literature reviewed here does not contain controlled human safety trials of tianeptine at the high exposures described in poison centre and case reports, and that absence is stated here as an absence rather than inferred from animal data (PMID 35211768).

Children and adolescents

A 2020 meta-review in Frontiers in Psychiatry examined the efficacy, tolerability and suicidality of antidepressants in children and adolescents in acute treatment, summarising what the paediatric evidence base supports across the class (PMID 32982805). A separate 2021 practitioner review examined pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder and reported the state of that trial evidence (PMID 32845025). Neither addresses tianeptine-specific paediatric adverse-effect rates, and no paper in the verified list supplies them.

Kidney disease

A 2012 systematic review by European Renal Best Practice examined the pharmacokinetics, efficacy and safety of antidepressants in stage 3–5 chronic kidney disease and issued recommendations based on that evidence (PMID 22859791). Reviews of this kind exist because impaired clearance can change exposure to drugs and their metabolites, which is a general safety consideration in the antidepressant class rather than a tianeptine-specific finding reported here.

Case reports as a form of evidence

Psychiatric case reports also document unexpected reactions to antidepressants generally, such as a report describing duloxetine-related panic attacks (PMID 21448113). Such reports generate hypotheses and alert clinicians to possibilities, but they cannot establish causation or frequency, which is the same constraint that applies to the tianeptine withdrawal report above (PMID 39022455).

Evidence at a glance

Limitations worth weighing

Four constraints shape every claim on this page. First, the strongest mechanistic adverse-effect data are preclinical and were obtained in male rodents (PMID 35211768). Second, the largest human dataset is passive surveillance in which product contents and amounts were generally unverified (PMID 30070980). Third, clinical withdrawal evidence rests substantially on individual cases (PMID 39022455). Fourth, whether the aggregate picture amounts to a population-level hazard or a narrower pattern of use remained an open question in the 2025 analysis (PMID 41084181).

What this page does not cover

This page is limited to what published studies reported about adverse effects, withdrawal and safety-related surveillance. Pharmacology, receptor mechanisms, regulatory history and how the compound has been studied as an antidepressant are taught in the PeptideU tianeptine course at /learn/tianeptine/, which is structured as instruction rather than as an adverse-event summary. Nothing here should be read as guidance on use, and no dose, schedule or comparison is provided. Regulatory status varies by country and changes over time; this page is educational and is not legal advice.

References

• Opioid-like adverse effects of tianeptine in male rats and mice (Psychopharmacology, 2022)
• Characteristics of Tianeptine Exposures Reported to the National Poison Data System - United States, 2000-2017 (MMWR, 2018)
• Tianeptine's Obscured Withdrawal, Presentation, and Treatment (Cureus, 2024)
• Tianeptine Products: Public Health Threat or Niche Substance use? (Journal of Psychoactive Drugs, 2025)
• Activation of μ receptors by SR-17018 through a distinctive mechanism (Neuropharmacology, 2024)
• Development of Dibenzothiazepine Derivatives as Multifunctional Compounds for Neuropathic Pain (Pharmaceuticals, 2022)
• Modulation of Proton-Gated Channels by Antidepressants (ACS Chemical Neuroscience, 2019)
• Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis (Molecular Psychiatry, 2023)
• Antidepressants in Children and Adolescents: Meta-Review of Efficacy, Tolerability and Suicidality in Acute Treatment (Frontiers in Psychiatry, 2020)
• Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder (Journal of Child Psychology and Psychiatry, 2021)
• Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (Nephrology Dialysis Transplantation, 2012)
• Duloxetine-related panic attacks (Psychiatria Danubina, 2011)